Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Tubiana-Mathieu N, Cany L, Catala S, Khayat D, Pauporté I, Kramar A; PHARE trial investigators. Pivot X, et al. Among authors: cany l. Lancet Oncol. 2013 Jul;14(8):741-8. doi: 10.1016/S1470-2045(13)70225-0. Epub 2013 Jun 11. Lancet Oncol. 2013. PMID: 23764181 Clinical Trial.
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.
Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Venat-Bouvet L, Cany L, Catala S, Khayat D, Gambotti L, Pauporté I, Faure-Mercier C, Paget-Bailly S, Henriques J, Grouin JM; PHARE trial investigators. Pivot X, et al. Among authors: cany l. Lancet. 2019 Jun 29;393(10191):2591-2598. doi: 10.1016/S0140-6736(19)30653-1. Epub 2019 Jun 6. Lancet. 2019. PMID: 31178155 Clinical Trial.
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.
Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, Smith I, Láng I, Wardley A, Rabaglio M, Price KN, Gelber RD, Coates AS, Thürlimann B; BIG 1-98 Collaborative Group; International Breast Cancer Study Group (IBCSG). Regan MM, et al. Lancet Oncol. 2011 Nov;12(12):1101-8. doi: 10.1016/S1470-2045(11)70270-4. Epub 2011 Oct 20. Lancet Oncol. 2011. PMID: 22018631 Free PMC article. Clinical Trial.
Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS 04 trial.
Roca L, Diéras V, Roché H, Lappartient E, Kerbrat P, Cany L, Chieze S, Canon JL, Spielmann M, Penault-Llorca F, Martin AL, Mesleard C, Lemonnier J, de Cremoux P. Roca L, et al. Among authors: cany l. Breast Cancer Res Treat. 2013 Jun;139(3):789-800. doi: 10.1007/s10549-013-2587-x. Epub 2013 Jun 19. Breast Cancer Res Treat. 2013. PMID: 23780683 Clinical Trial.
Subcutaneous interleukin-2, interferon alpha-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a phase II trial.
Ravaud A, Trufflandier N, Ferrière JM, Debled M, Palussière J, Cany L, Gaston R, Mathoulin-Pélissier S, Bui BN. Ravaud A, et al. Among authors: cany l. Br J Cancer. 2003 Dec 15;89(12):2213-8. doi: 10.1038/sj.bjc.6601419. Br J Cancer. 2003. PMID: 14676797 Free PMC article. Clinical Trial.
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.
BIG 1-98 Collaborative Group; Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thürlimann B, Paridaens R, Smith I, Mauriac L, Forbes J, Price KN, Regan MM, Gelber RD, Coates AS. BIG 1-98 Collaborative Group, et al. N Engl J Med. 2009 Aug 20;361(8):766-76. doi: 10.1056/NEJMoa0810818. N Engl J Med. 2009. PMID: 19692688 Free PMC article. Clinical Trial.
Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer.
Giobbie-Hurder A, Price KN, Gelber RD; International Breast Cancer Study Group; BIG 1-98 Collaborative Group. Giobbie-Hurder A, et al. Clin Trials. 2009 Jun;6(3):272-87. doi: 10.1177/1740774509105380. Clin Trials. 2009. PMID: 19528136 Free PMC article. Clinical Trial.
The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause.
Chirgwin J, Sun Z, Smith I, Price KN, Thürlimann B, Ejlertsen B, Bonnefoi H, Regan MM, Goldhirsch A, Coates AS; BIG 1-98 Collaborative and International Breast Cancer Study Groups. Chirgwin J, et al. Breast Cancer Res Treat. 2012 Jan;131(1):295-306. doi: 10.1007/s10549-011-1741-6. Epub 2011 Sep 4. Breast Cancer Res Treat. 2012. PMID: 21892704 Free PMC article. Clinical Trial.
Summary version of the Standards, Options and Recommendations for nonmetastatic breast cancer (updated January 2001).
Mauriac L, Luporsi E, Cutuli B, Fourquet A, Garbay JR, Giard S, Spyratos F, Sigal-Zafrani B, Dilhuydy JM, Acharian V, Balu-Maestro C, Blanc-Vincent MP, Cohen-Solal C, De Lafontan B, Dilhuydy MH, Duquesne B, Gilles R, Lesur A, Shen N, Cany L, Dagousset I, Gaspard MH, Hoarau H, Hubert A, Monira MH, Perrié N, Romieu G; FNCLCC. Mauriac L, et al. Among authors: cany l. Br J Cancer. 2003 Aug;89 Suppl 1(Suppl 1):S17-31. doi: 10.1038/sj.bjc.6601081. Br J Cancer. 2003. PMID: 12915900 Free PMC article. No abstract available.
49 results